StemRIM (4599.T)
JPY 298.0
(0.0%)
JPY 298.0
(0.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 | 29 Million JPY | 244.54% |
| 2023 | 8.51 Million JPY | 95.81% |
| 2022 | 4.34 Million JPY | -64.1% |
| 2021 | 12.11 Million JPY | -32.89% |
| 2020 | 18.04 Million JPY | 42.69% |
| 2019 | 12.64 Million JPY | 22.26% |
| 2018 | 10.34 Million JPY | -84.39% |
| 2017 | 66.28 Million JPY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 34.87 Million JPY | 280.37% |
| 2024 Q1 | 9.16 Million JPY | 7.69% |
| 2024 Q4 | 29 Million JPY | 69.38% |
| 2024 Q3 | 17.31 Million JPY | -50.34% |
| 2023 Q3 | 9.59 Million JPY | -32.03% |
| 2023 Q2 | 14.11 Million JPY | -3.14% |
| 2023 Q4 | 8.51 Million JPY | -11.25% |
| 2023 Q1 | 14.57 Million JPY | 235.12% |
| 2023 FY | 8.51 Million JPY | 95.81% |
| 2022 Q3 | 3.77 Million JPY | -38.53% |
| 2022 Q2 | 6.13 Million JPY | -25.32% |
| 2022 Q1 | 8.21 Million JPY | -32.14% |
| 2022 Q4 | 4.34 Million JPY | 15.24% |
| 2022 FY | 4.34 Million JPY | -64.1% |
| 2021 Q4 | 12.11 Million JPY | 1.96% |
| 2021 FY | 12.11 Million JPY | -32.89% |
| 2021 Q1 | 12.33 Million JPY | -31.65% |
| 2021 Q3 | 11.87 Million JPY | 2.76% |
| 2021 Q2 | 11.55 Million JPY | -6.3% |
| 2020 Q4 | 18.04 Million JPY | 6.4% |
| 2020 Q2 | 8.95 Million JPY | -19.45% |
| 2020 Q1 | 11.12 Million JPY | -12.08% |
| 2020 FY | 18.04 Million JPY | 42.69% |
| 2020 Q3 | 16.96 Million JPY | 89.37% |
| 2019 Q4 | 12.64 Million JPY | -33.03% |
| 2019 Q3 | 18.88 Million JPY | 0.0% |
| 2019 FY | 12.64 Million JPY | 22.26% |
| 2018 FY | 10.34 Million JPY | -84.39% |
| 2017 FY | 66.28 Million JPY | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 683.01 Million JPY | 95.754% |
| PRISM BioLab Co.,LTD | 17.92 Million JPY | -61.749% |
| GNI Group Ltd. | 2.33 Billion JPY | 98.756% |
| Linical Co., Ltd. | - JPY | -Infinity% |
| Trans Genic Inc. | 2.22 Billion JPY | 98.698% |
| MEDINET Co., Ltd. | 67.48 Million JPY | 57.025% |
| Soiken Holdings Inc. | 1.12 Billion JPY | 97.413% |
| Cytori Cell Research Institute, Inc. | 103.53 Million JPY | 71.99% |
| AnGes, Inc. | 1.61 Billion JPY | 98.205% |
| OncoTherapy Science, Inc. | 73.99 Million JPY | 60.81% |
| Nxera Pharma Co., Ltd. | 2.9 Billion JPY | 99.001% |
| Immuno-Biological Laboratories Co., Ltd. | 321.91 Million JPY | 90.991% |
| NanoCarrier Co., Ltd. | 184 Thousand JPY | -15660.87% |
| Carna Biosciences, Inc. | 140.14 Million JPY | 79.306% |
| CanBas Co., Ltd. | 728 Thousand JPY | -3883.516% |
| D. Western Therapeutics Institute, Inc. | 87.86 Million JPY | 66.994% |
| RaQualia Pharma Inc. | 147.93 Million JPY | 80.397% |
| Chiome Bioscience Inc. | 64.1 Million JPY | 54.763% |
| Kidswell Bio Corporation | 875.65 Million JPY | 96.688% |
| PeptiDream Inc. | 2.4 Billion JPY | 98.794% |
| Oncolys BioPharma Inc. | 5.34 Million JPY | -442.868% |
| Ribomic Inc. | 2.27 Million JPY | -1175.286% |
| SanBio Company Limited | - JPY | -Infinity% |
| Healios K.K. | - JPY | -Infinity% |
| BrightPath Biotherapeutics Co., Ltd. | 1.00 JPY | -2899999900.0% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 36 Million JPY | 19.444% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| CellSource Co., Ltd. | 305.92 Million JPY | 90.521% |
| FunPep Company Limited | 25.54 Million JPY | -13.543% |
| Kringle Pharma, Inc. | 364.05 Million JPY | 92.034% |
| Stella Pharma Corporation | 1.11 Billion JPY | 97.402% |
| TMS Co., Ltd. | 50.02 Million JPY | 42.029% |
| Noile-Immune Biotech Inc. | 20.9 Million JPY | -38.749% |
| Cuorips Inc. | 1.04 Million JPY | -2680.441% |
| K Pharma,Inc. | 10.79 Million JPY | -168.668% |
| Takara Bio Inc. | 11.85 Billion JPY | 99.755% |
| ReproCELL Incorporated | 248.14 Million JPY | 88.313% |
| PhoenixBio Co., Ltd. | 450.58 Million JPY | 93.564% |
| StemCell Institute Inc. | 42.26 Million JPY | 31.38% |
| Japan Tissue Engineering Co., Ltd. | 228.56 Million JPY | 87.312% |
| CellSeed Inc. | 46.19 Million JPY | 37.217% |